Evidence map›Paper›PMID 38480728›Full record

ArticleNature communications2024

Inter-species gene flow drives ongoing evolution of Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis.

Ouli Xie, Jacqueline M Morris, Andrew J Hayes, Rebecca J Towers, Magnus G Jespersen, John A Lees, Nouri L Ben Zakour, Olga Berking, Sarah L Baines, Glen P Carter and 22 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Genomic and patient epidemiology ofMicrobiology spectrum · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Analysis ofmBio · 2025
    Article
  13. Article
  14. InvasiveOxford medical case reports · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Clinical microbiology reviews · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 17 institutions in 6 countries.

Ouli XieDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-5032-1932
Jacqueline M MorrisDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-4934-7369
Andrew J HayesDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0001-8038-1656
Rebecca J TowersMenzies School of Health Research, Charles Darwin University, Darwin, Australia.
Magnus G JespersenDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0001-9751-9877
John A LeesEuropean Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, Cambridgeshire, UK.ORCID 0000-0001-5360-1254
Nouri L Ben ZakourAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.ORCID 0000-0002-6949-1755
Olga BerkingAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
Sarah L BainesDoherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-0557-0518
Glen P CarterDoherty Applied Microbial Genomics, Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-7306-9362
Gerry Tonkin-HillDepartment of Biostatistics, University of Oslo, Oslo, Norway.
Layla SchrieberFaculty of Veterinary Science, The University of Sydney, Sydney, Australia.
Liam McIntyreDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Jake A LaceyDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-6492-6983
Taylah B JamesDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Kadaba S SriprakashInfection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Scott A BeatsonAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.ORCID 0000-0002-1806-3283
Tadao HasegawaDepartment of Bacteriology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Phil GiffardMenzies School of Health Research, Charles Darwin University, Darwin, Australia.
Andrew C SteerTropical Diseases, Murdoch Children's Research Institute, Parkville, Australia.ORCID 0000-0001-7346-0196
Michael R BatzloffInfection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Bernard W BeallRespiratory Disease Branch, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0001-5315-1070
Marcos D PinhoInstituto de Microbiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Mario RamirezInstituto de Microbiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Debra E BessenDepartment of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY, USA.
Gordon DouganParasites and Microbes, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Stephen D BentleyParasites and Microbes, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID 0000-0001-8094-3751
Mark J WalkerAustralian Infectious Diseases Research Centre and School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.ORCID 0000-0001-7423-2769
Bart J CurrieMenzies School of Health Research, Charles Darwin University, Darwin, Australia.ORCID 0000-0002-8878-8837
Steven Y C TongDepartment of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-1368-8356
David J McMillan *School of Science, Technology and Engineering, and Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Australia.
Mark R Davies *Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. mark.davies1@unimelb.edu.au.ORCID 0000-0001-6141-5179
The University of Melbourne · AUThe University of Queensland · AUCharles Darwin University · AUUniversity of Lisbon · PTWellcome Sanger Institute · GBCenters for Disease Control and Prevention · USEuropean Bioinformatics Institute · GBGriffith University · AUMurdoch Children's Research Institute · AUNagoya City University · JPNew York Medical College · USPeter Doherty Institute · AUQIMR Berghofer Medical Research Institute · AUThe Royal Melbourne Hospital · AUThe University of Sydney · AUUniversity of Oslo · NOUniversity of the Sunshine Coast · AU

Funding

Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate ModelsR01AI173689 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victor Nizet, Mark Joseph Walker · 2023 to 2026
$2.8M
Protective antibody in streptococcal infection modelsR01AI173565 · NIAID · NEW YORK MEDICAL COLLEGE · PI Debra E BESSEN · 2023 to 2026
$1.8M
Macrolide resistance transfer in Streptococcus pyogenesR21AI156226 · NIAID · NEW YORK MEDICAL COLLEGE · PI BESSEN, DEBRA E · 2021 to 2022
$461k
Pilin Genotyping for Group A StreptococciR03AI148983 · NIAID · NEW YORK MEDICAL COLLEGE · PI BESSEN, DEBRA E · 2020 to 2021
$161k
NIAID NIH HHS R01 AI173565NIAID NIH HHS R01 AI173689NIAID NIH HHS R03 AI148983NIAID NIH HHS R21 AI156226Wellcome TrustWellcome Trust 108413/A/15/DWellcome Trust 206194
6 · The paper itself

Abstract

Streptococcus dysgalactiae subsp. equisimilis (SDSE) is an emerging cause of human infection with invasive disease incidence and clinical manifestations comparable to the closely related species, Streptococcus pyogenes. Through systematic genomic analyses of 501 disseminated SDSE strains, we demonstrate extensive overlap between the genomes of SDSE and S. pyogenes. More than 75% of core genes are shared between the two species with one third demonstrating evidence of cross-species recombination. Twenty-five percent of mobile genetic element (MGE) clusters and 16 of 55 SDSE MGE insertion regions were shared across species. Assessing potential cross-protection from leading S. pyogenes vaccine candidates on SDSE, 12/34 preclinical vaccine antigen genes were shown to be present in >99% of isolates of both species. Relevant to possible vaccine evasion, six vaccine candidate genes demonstrated evidence of inter-species recombination. These findings demonstrate previously unappreciated levels of genomic overlap between these closely related pathogens with implications for streptococcal pathobiology, disease surveillance and prevention.

Indexed as

Streptococcal InfectionsStreptococcusVaccinesGene FlowHumansStreptococcus pyogenesVaccines

Identifiers

PMID38480728
PMCPMC10937727
OpenAlexW4392746819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.